Invesco Ltd. Cogent Biosciences, Inc. Call Options Transaction History
Invesco Ltd.
- $516 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding COGT
# of Institutions
190Shares Held
104MCall Options Held
157KPut Options Held
439K-
Kynam Capital Management, LP Princeton, NJ9.11MShares$69.8 Million4.5% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$55.9 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$53.4 Million8.87% of portfolio
-
Commodore Capital LP New York, NY6.88MShares$52.8 Million5.38% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA6.23MShares$47.8 Million9.76% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $504M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...